July 25th 2024
Initial approval for maralixibat was granted on March 13, 2024, to treat PFIC patients aged 5 years and older.
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Available biologics for treating asthma and allergic skin disease
October 11th 2021In cases of poorly controlled disease, even with good medication adherence, it might make sense to turn to biologics. A presentation at the virtual 2021 American Academy of Pediatrics National Conference & Exhibition covered biologics available for treating asthma and allergic skin disease.
Pearls for treating dermatologic conditions in skin of color
October 9th 2021Treating dermatologic conditions in skin of color requires cultural awareness and sensitivity, in addition to being aware of how presentation may differ. At the virtual 2021 American Academy of Pediatrics National Conference & Exhibition, a session offered clinical pearls.